Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Increase in Short Interest

Aptevo Therapeutics Inc. (NASDAQ:APVO) saw a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 34,300 shares, a growth of 18.7% from the March 15th total of 28,900 shares. Based on an average trading volume of 122,800 shares, the short-interest ratio is presently 0.3 days. Currently, 5.1% of the company’s stock are sold short.

Institutional Investors Weigh In On Aptevo Therapeutics

A number of large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP acquired a new stake in Aptevo Therapeutics in the 4th quarter worth approximately $29,000. Virtu Financial LLC purchased a new stake in Aptevo Therapeutics during the 2nd quarter worth approximately $46,000. Citadel Advisors LLC purchased a new stake in Aptevo Therapeutics during the 4th quarter worth approximately $47,000. Renaissance Technologies LLC grew its position in Aptevo Therapeutics by 45.8% during the 2nd quarter. Renaissance Technologies LLC now owns 80,186 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 25,200 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Aptevo Therapeutics during the 1st quarter worth approximately $152,000. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Aptevo Therapeutics in a report on Wednesday. They issued a “hold” rating on the stock.

Aptevo Therapeutics Stock Down 11.8 %

Shares of NASDAQ:APVO opened at $0.85 on Friday. The business’s 50-day moving average is $5.26 and its 200 day moving average is $8.22. Aptevo Therapeutics has a 1 year low of $0.83 and a 1 year high of $91.96.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.